Understanding the role of cFLIP in B cell lymphoma pathogenesis

Mutations that impair B lymphocyte death lead to immune disorders, including lymphadenopathy, splenomegaly and B cell lymphoma. cFLIP is a key cell death inhibitor whose elevated expression has been frequently associated with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) and correlates with tumor progression and poor clinical outcome. However, the exact role of cFLIP in B-cell biology and lymphomagenesis has not been elucidated, yet. The major objective of this project is to characterize the role of cFLIP in the pathogenesis and progression of DLBCL and determine how its inhibition could be exploited for the treatment of lymphoma.


Dr. rer. nat. Alessandro Annibaldi

Laboratory of Cell Death, Inflammation and Immunity

CMMC - Center for Molecular Medicine Cologne

University of Cologne

Robert-Koch-Straße 21

50931 Cologne